377 related articles for article (PubMed ID: 31043094)
1. Fremanezumab as a preventive treatment for episodic and chronic migraine.
Bigal ME; Walter S; Rapoport AM
Expert Rev Neurother; 2019 Aug; 19(8):719-728. PubMed ID: 31043094
[No Abstract] [Full Text] [Related]
2. Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine.
Friedman DI; Cohen JM
Emerg Top Life Sci; 2020 Sep; 4(2):179-190. PubMed ID: 32832978
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine.
Parikh SK; Burkett JG; Silberstein SD
Expert Opin Drug Saf; 2020 May; 19(5):537-543. PubMed ID: 32116061
[No Abstract] [Full Text] [Related]
4. Fremanezumab for the preventive treatment of migraine.
Silberstein SD; Cohen JM; Yeung PP
Expert Opin Biol Ther; 2019 Aug; 19(8):763-771. PubMed ID: 31177856
[No Abstract] [Full Text] [Related]
5. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
Alex A; Vaughn C; Rayhill M
Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
[TBL] [Abstract][Full Text] [Related]
6. Fremanezumab for the Preventive Treatment of Chronic Migraine.
Silberstein SD; Dodick DW; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
N Engl J Med; 2017 Nov; 377(22):2113-2122. PubMed ID: 29171818
[TBL] [Abstract][Full Text] [Related]
7. Fremanezumab for the preventive treatment of migraine in adults.
Lionetto L; Curto M; Cisale GY; Capi M; Cipolla F; Guglielmetti M; Martelletti P
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):741-748. PubMed ID: 31220963
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
Ashina M; Cohen JM; Galic M; Campos VR; Barash S; Ning X; Kessler Y; Janka L; Diener HC
J Headache Pain; 2021 Jul; 22(1):68. PubMed ID: 34246226
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Sakai F; Suzuki N; Kim BK; Tatsuoka Y; Imai N; Ning X; Ishida M; Nagano K; Iba K; Kondo H; Koga N
Headache; 2021 Jul; 61(7):1102-1111. PubMed ID: 34323290
[TBL] [Abstract][Full Text] [Related]
10. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Ferrari MD; Diener HC; Ning X; Galic M; Cohen JM; Yang R; Mueller M; Ahn AH; Schwartz YC; Grozinski-Wolff M; Janka L; Ashina M
Lancet; 2019 Sep; 394(10203):1030-1040. PubMed ID: 31427046
[TBL] [Abstract][Full Text] [Related]
11. Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
Ashina M; Cohen JM; Gandhi SK; Du E
Headache; 2021 Jun; 61(6):916-926. PubMed ID: 34115380
[TBL] [Abstract][Full Text] [Related]
12. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
[TBL] [Abstract][Full Text] [Related]
13. From LBR-101 to Fremanezumab for Migraine.
Bigal ME; Rapoport AM; Silberstein SD; Walter S; Hargreaves RJ; Aycardi E
CNS Drugs; 2018 Nov; 32(11):1025-1037. PubMed ID: 30311143
[TBL] [Abstract][Full Text] [Related]
14. Galcanezumab for the prevention of migraine.
Frerichs LM; Friedman DI
Pain Manag; 2021 Mar; 11(2):101-112. PubMed ID: 33291980
[TBL] [Abstract][Full Text] [Related]
15. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
16. Fremanezumab: First Global Approval.
Hoy SM
Drugs; 2018 Nov; 78(17):1829-1834. PubMed ID: 30406901
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study.
Sakai F; Suzuki N; Ning X; Ishida M; Usuki C; Iba K; Isogai Y; Koga N
Drug Saf; 2021 Dec; 44(12):1355-1364. PubMed ID: 34687446
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis.
Deng H; Li GG; Nie H; Feng YY; Guo GY; Guo WL; Tang ZP
BMC Neurol; 2020 Feb; 20(1):57. PubMed ID: 32061264
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Sakai F; Suzuki N; Kim BK; Igarashi H; Hirata K; Takeshima T; Ning X; Shima T; Ishida M; Iba K; Kondo H; Koga N
Headache; 2021 Jul; 61(7):1092-1101. PubMed ID: 34324700
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.
Goadsby PJ; Silberstein SD; Yeung PP; Cohen JM; Ning X; Yang R; Dodick DW
Neurology; 2020 Nov; 95(18):e2487-e2499. PubMed ID: 32913018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
